Companies › AskBio France, SAS, a subsidiary of AskBio
1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Apr 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AB-1001 (AAVrh10.CAG.hCYP46A1) AAV-mediated gene delivery of human cholesterol 24-hydroxylase (CYP46A1) | CYP46A1 | Phase 1 | Huntington Disease | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05541627 | AB-1001 (AAVrh10.CAG.hCYP46A1) | Phase 1 | Huntington Disease | Neurology | Apr 2028 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.